INACTIVATED INFLUENZA VACCINE (SPLIT VIRON) BP Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

inactivated influenza vaccine (split viron) bp

sanofi pasteur msd ltd - a/california/7/2009 (h1n1)v like strain (x-179a) a/california/7/2009 (h1n1) - derived strain used nymc x-181 reass b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 7.5 mcg ea %v/v

SEREPAX oxazepam 15 mg tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

serepax oxazepam 15 mg tablet blister pack

aspen pharma pty ltd - oxazepam, quantity: 15 mg - tablet, uncoated - excipient ingredients: magnesium stearate; polacrilin potassium; lactose monohydrate; microcrystalline cellulose - indications as at 22 feb 1995 : management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety associated with depression is also responsive to serepax therapy. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal are reponsive to therapy.

SEREPAX oxazepam 30 mg tablet blister pack Australia - Inggris - Department of Health (Therapeutic Goods Administration)

serepax oxazepam 30 mg tablet blister pack

aspen pharma pty ltd - oxazepam, quantity: 30 mg - tablet, uncoated - excipient ingredients: magnesium stearate; methylcellulose; polacrilin potassium; lactose monohydrate; sunset yellow fcf - indications as at 22 feb 1995 : management of anxiety disorders or for the short-term relief of the symptoms of anxiety. anxiety associated with depression is also responsive to serepax therapy. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the physician should periodically reassess the usefulness of the drug for the individual patient. alcoholics with acute tremulousness, confusional state or anxiety associated with alcohol withdrawal are reponsive to therapy.

INACTIVATED INFLUENZA VACCINE (SPLIT VIRON) 7.5 mcg ea %v/v Suspension for Injection Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

inactivated influenza vaccine (split viron) 7.5 mcg ea %v/v suspension for injection

sanofi pasteur msd ltd - a/california/7/2009 (h1n1)pdm09 - derived strain used nymc x-179a a/victoria/361/2011 (h3n2) - derived strain used ivr-165 b/massachusetts/2/2012 - suspension for injection - 7.5 mcg ea %v/v

Prepandrix Uni Eropa - Inggris - EMA (European Medicines Agency)

prepandrix

glaxosmithkline biologicals s.a. - a/indonesia/05/2005 (h5n1) like strain used (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza-a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared with h5n1 subtype strains.prepandrix should be used in accordance with official guidance.

Bulk Quadrivalent Influenza Vaccine (split virion, inactivated) Thiomersal containing Australia - Inggris - Department of Health (Therapeutic Goods Administration)

bulk quadrivalent influenza vaccine (split virion, inactivated) thiomersal containing

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: monobasic potassium phosphate; water for injections; thiomersal; calcium chloride dihydrate; dibasic sodium phosphate; potassium chloride; sodium chloride; monobasic sodium phosphate - for active immunization against influenza disease caused by influenza subtype viruses and type b viruses contained in the vaccine.

Bulk Quadrivalent Influenza Vaccine (split virion, inactivated) Australia - Inggris - Department of Health (Therapeutic Goods Administration)

bulk quadrivalent influenza vaccine (split virion, inactivated)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: dibasic sodium phosphate; water for injections; monobasic potassium phosphate; sodium chloride; potassium chloride; calcium chloride dihydrate; monobasic sodium phosphate - for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine.